行业周报：脑机接口发展加速，商业落地前景可期-2025-03-30

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Insights - The brain-computer interface (BCI) technology is experiencing rapid development and has promising commercial prospects, with a focus on diverse technical paths and applications in the medical field [5][6][32] - The BCI technology is categorized into invasive, semi-invasive, and non-invasive types, each with its own advantages in signal quality, safety, and operational difficulty [18][20] - The core technological barriers of BCI are concentrated in the upstream of the industry chain, including hardware (electrodes, chips), surgical procedures, and signal processing [25][28] Summary by Sections 1. BCI Development and Applications - BCI is a multidisciplinary technology that integrates neuroscience, computer science, and engineering to facilitate communication between the brain and external devices [15] - The medical application of BCI is predominant, accounting for 56% of the market in 2023, with potential in diagnosing and treating cognitive disorders, mental illnesses, and motor disabilities [33][36] 2. BCI Policy and Pricing - The National Healthcare Security Administration has established a pricing standard for BCI services, addressing the slow commercialization of BCI technology and creating a pricing framework that covers the entire service chain [40][42] 3. BCI Companies and Market Trends - Non-invasive BCI products are leading in commercialization, while invasive and semi-invasive products are still in clinical research stages [43] - Key companies in the BCI space include NeuroPace, BrainGate, Neuralink, and Paradromics, each focusing on various applications such as epilepsy treatment and motor function recovery [43]